Xeris Biopharma Holdings, Inc. (XERS) — Stock Score Summary

Xeris Biopharma Holdings, Inc. (XERS) has a MoatMap StockRank of 36/100 based on Quality (58/100), Value (25/100), and Momentum (41/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price$6.32
Market Cap$1.1B
P/E (TTM)89.43
P/E (Forward)15.85
Price/Book76.34
Return on Invested Capital10.8%
Debt/Equity1987.19
Gross Margin85.9%
Operating Margin9.5%
Revenue Growth38.3%
Free Cash Flow$42M

Xeris Biopharma Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Xeris Biopharma Holdings, Inc.’s (XERS) StockRank?
MoatMap’s StockRank for Xeris Biopharma Holdings, Inc. (XERS) is 36/100, with a Hold signal. It is a composite of Quality (58), Value (25), and Momentum (41) factor ranks across MoatMap’s 19,000+ stock universe.
Does Xeris Biopharma Holdings, Inc. have an economic moat?
Xeris Biopharma Holdings, Inc. (XERS) has a Quality factor score of 58/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Xeris Biopharma Holdings, Inc. a buy, hold, or sell?
MoatMap’s current signal for Xeris Biopharma Holdings, Inc. (XERS) is Hold, based on a StockRank of 36/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Xeris Biopharma Holdings, Inc. in?
Xeris Biopharma Holdings, Inc. (XERS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksXERS deep dive reportAI ChampionsHow we score stocksSense-check another stock